Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Extracellular Matrix

The Extracellular Matrix

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cholangiocyte RUNX1 Orchestrates Fibrogenic and Inflammatory Signaling to Drive Biliary Fibrosis.

bioRxiv : the preprint server for biology·2026

Same author

Local Lung HIF-1α and VEGF Activation to Reverse Emphysema by a Sulfated Caffeic Acid Dehydropolymer.

Biology·2026

Same author

Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.

Pharmacological reviews·2026

Same author

The Impact of Enteral Nutrition Type, Volume, and Time of Introduction on the Risk of Growth Failure and Bronchopulmonary Dysplasia in Preterm Infants.

Nutrients·2026

Same author

Bile acid dysmetabolism in Bangladeshi infants associated with poor linear growth, enteric inflammation, and small intestine bacterial overgrowth.

World journal of gastroenterology·2025

Same author

Exploring the Impact of E-cigarettes on Cardiovascular Health: Insights from Preclinical and Clinical Studies.

Cardiovascular toxicology·2025

Search research articles

Related Experiment Video

Updated: Sep 11, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections.

Raahi Patel¹, Ignacio Moyano¹, Masahiro Sakagami²

¹Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23219, USA.

International Journal of Molecular Sciences

|August 14, 2025

Summary

Novel nanoparticles combining levofloxacin (LVX) and extracellular matrix (ECM) show promise for treating cystic fibrosis lung infections. These LVX-ECM nanoparticles effectively target bacteria and are non-toxic to lung cells.

Keywords:

cystic fibrosis extracellular matrix levofloxacin mucus barrier nanoparticles pulmonary delivery

More Related Videos

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections

Published on: October 31, 2017

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Related Experiment Videos

Last Updated: Sep 11, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections

Published on: October 31, 2017

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Area of Science:

Biomedical Engineering
Nanotechnology
Pulmonary Medicine

Background:

Cystic fibrosis (CF) involves viscous lung mucus, increasing susceptibility to bacterial infections like *Pseudomonas aeruginosa* and *Staphylococcus aureus*.
These common CF pathogens are often antibiotic-resistant, necessitating novel therapeutic strategies.
Levofloxacin (LVX) is an antibiotic used for these infections, but its delivery can be improved.

Purpose of the Study:

To develop and evaluate hybrid nanoparticles combining levofloxacin (LVX) and extracellular matrix (ECM) for enhanced pulmonary delivery in cystic fibrosis.
To assess the potential of these nanoparticles to overcome the mucus barrier and effectively treat bacterial lung infections in CF.

Main Methods:

Formulation of hybrid nanoparticles with LVX and ECM in 10:1 and 1:1 ratios.
Characterization of nanoparticle surface charge, size, and drug dissolution profiles.
In vitro assessment of nanoparticle toxicity to human airway epithelial cells and efficacy against *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

Main Results:

Two hybrid formulations exhibited neutral surface charges and average sizes of ~525 nm (10:1) and ~300 nm (1:1).
Nanoparticles demonstrated slowed drug dissolution, were non-toxic to human airway epithelial cells, and effectively inhibited the growth of *Pseudomonas aeruginosa* and *Staphylococcus aureus*.
Particle size and neutral charge suggest potential for mucus penetration and bacterial targeting.

Conclusions:

LVX-ECM nanoparticles represent a promising, non-toxic inhaled therapy for cystic fibrosis lung infections.
This hybrid formulation may offer an improved treatment option by addressing both bacterial burden and potentially aiding lung repair.
Further development of LVX-ECM nanoparticles could advance care for pulmonary bacterial infections in CF patients.